PRAX Quote, Financials, Valuation and Earnings

GRAIL, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -245.83%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat GRAIL, Inc.'s return on equity of -16.84%.

Praxis Precision Medicines, Inc. has a consensus price target of $461.73, signalling upside risk potential of 60.07%. On the other hand GRAIL, Inc. has an analysts' consensus of $105.00 which suggests that it could grow by 4.9%. Given that Praxis Precision Medicines, Inc. has higher upside potential than GRAIL, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than GRAIL, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.851, which suggesting that the stock is 185.093% more volatile than S&P 500. In comparison GRAIL, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GRAIL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. GRAIL, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than GRAIL, Inc. quarterly revenues of $36.2M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is higher than GRAIL, Inc.'s net income of -$89M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while GRAIL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 816.38x versus 24.72x for GRAIL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MIRA Pharmaceuticals, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of --. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat MIRA Pharmaceuticals, Inc.'s return on equity of -935.53%.

Praxis Precision Medicines, Inc. has a consensus price target of $461.73, signalling upside risk potential of 60.07%. On the other hand MIRA Pharmaceuticals, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 1099.32%. Given that MIRA Pharmaceuticals, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe MIRA Pharmaceuticals, Inc. is more attractive than Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.851, which suggesting that the stock is 185.093% more volatile than S&P 500. In comparison MIRA Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MIRA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. MIRA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than MIRA Pharmaceuticals, Inc. quarterly revenues of --. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than MIRA Pharmaceuticals, Inc.'s net income of -$22.7M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while MIRA Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 816.38x versus -- for MIRA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -162.11%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

Praxis Precision Medicines, Inc. has a consensus price target of $461.73, signalling upside risk potential of 60.07%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 293.33%. Given that Marker Therapeutics, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.851, which suggesting that the stock is 185.093% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 816.38x versus 5.42x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -49.03%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Praxis Precision Medicines, Inc. has a consensus price target of $461.73, signalling upside risk potential of 60.07%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.71 which suggests that it could grow by 37.51%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Viridian Therapeutics, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.851, which suggesting that the stock is 185.093% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.945, suggesting its less volatile than the S&P 500 by 5.488%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 816.38x versus 34.79x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.